Home » Stocks » ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. (ANIP)

Stock Price: $30.37 USD 0.87 (2.95%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 374.01M
Revenue (ttm) 197.55M
Net Income (ttm) -20.29M
Shares Out 12.32M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE 8.29
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $30.37
Previous Close $29.50
Change ($) 0.87
Change (%) 2.95%
Day's Open 29.22
Day's Range 28.95 - 30.60
Day's Volume 73,424
52-Week Range 25.23 - 80.87

More Stats

Market Cap 374.01M
Enterprise Value 531.51M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 12.32M
Float 9.27M
EPS (basic) -1.7
EPS (diluted) -0.12
FCF / Share 3.65
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 11.68%
Payout Ratio n/a
Shares Short 542,585
Short Ratio 4.39
Short % of Float 6.88%
Beta 1.53
PE Ratio n/a
Forward PE 8.29
P/FCF Ratio 8.56
PS Ratio 1.89
PB Ratio 1.90
Revenue 197.55M
Operating Income -16.74M
Net Income -20.29M
Free Cash Flow 43.70M
Net Cash -157.50M
Net Cash / Share -12.79
Gross Margin 72.59%
Operating Margin -8.47%
Profit Margin -10.30%
FCF Margin 22.12%
ROA -2.25%
ROE -10.17%
ROIC -5.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 1
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$42.67*
(40.50% upside)
Low
40.0
Current: $30.37
High
48.0
Target: 42.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue20720217712976.3255.9730.0820.370.442.47
Revenue Growth2.47%13.99%37.49%68.53%36.36%86.06%47.67%4581.27%-82.41%-
Gross Profit14312997.8179.8463.6344.5020.1111.200.442.47
Operating Income16.1234.8128.3820.0132.7420.170.59-0.28-50.93-43.61
Net Income6.0915.49-1.083.9315.3828.750.30-1.51-51.61-46.20
Shares Outstanding12.0411.7711.5511.5711.5611.055.073.632.731.83
Earnings Per Share0.501.30-0.090.341.322.59-0.92-7.62-18.90-25.26
EPS Growth-61.54%---74.24%-49.03%-----
Operating Cash Flow45.6367.0739.4227.4717.2622.03-5.48-0.14-47.87-40.10
Capital Expenditures-6.64-5.74-10.37-4.57-32.68-35.75-0.19-0.29-0.72-0.06
Free Cash Flow39.0061.3329.0522.91-15.42-13.72-5.68-0.43-48.59-40.16
Cash & Equivalents67.3648.0336.1532.3715516911.110.0157.3138.26
Total Debt186183202121113107-4.0717.3418.55
Net Cash / Debt-118-135-165-88.2841.2662.5011.11-4.0539.9719.71
Assets45743141232328526044.5013.7562.3844.77
Liabilities2442332371531251203.5456.4624.5625.62
Book Value21319717517016014040.96-42.7237.8219.15
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ANI Pharmaceuticals, Inc.
Country United States
Employees 338
CEO Patrick D. Walsh

Stock Information

Ticker Symbol ANIP
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ANIP

Description

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company offers pharmaceuticals for the treatment of breast cancer, hypertension, ventricular arrhythmias, stage D2 metastatic carcinoma of the prostate, depression, diarrhea, infections, vasomotor symptoms of menopause, pain caused by osteoarthritis and rheumatoid arthritis, epilepsy, arrhythmia, obsessive-compulsive disorder and social anxiety disorder, ulcerative colitis, salt and fluid retention, manic episodes of bipolar disorder, ulcerative colitis, proctosigmoiditis, ocular conditions, metastatic prostate cancer, arrhythmia, migraine headache, and enterocolitis caused by staphylococcus aureus. It also provides aspirin and extended-release dipyridamole; Cholestyramine, an adjunctive therapy to diet for the reduction of elevated serum cholesterol; Ezetimibe-Simvastatin to lower high cholesterol and triglyceride levels; Fenofibrate, a peroxisome proliferator receptor alpha activator; Hydrocortisone rectal cream for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Morphine Sulfate, an oral solution for acute and chronic pain management; Nimodipine to enhance neurological outcomes; and Terbutaline Sulfate for the prevention and reversal of bronchospasm. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.